Castle Biosciences (CSTL) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon and welcome to Castle Biosciences First Quarter twenty twenty five Conference Call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would like to turn the call over to Camilla Zuccaro, Vice President of Investor Relations and Corporate Affairs. Please go ahead. Speaker1 Thank you, operator. Good afterno ...

Core Insights - Castle Biosciences, Inc. reported a 21% increase in Q1 2025 revenue to $88 million compared to Q1 2024 [1] - The company raised its full-year 2025 revenue guidance to $287-297 million from the previous range of $280-295 million [1][6] - The total test reports for core revenue drivers increased by 33% over Q1 2024 [1] Financial Performance - Revenues for Q1 2025 were $88 million, up from $73 million in Q1 2024, representing a 21% increase [4] - Adjusted revenues, excluding prior period adjustments, were $87.2 million, a 22% increase from $71.3 million in the same period last year [4] - The gross margin was 49%, while the adjusted gross margin remained at 81% [4] - The net loss for Q1 2025 was $25.8 million, compared to a net loss of $2.5 million in Q1 2024 [4][8] Operational Highlights - The company delivered 24,402 total test reports in Q1 2025, a 17% increase from 20,888 in Q1 2024 [4] - DecisionDx-Melanoma surpassed 200,000 test orders since its launch, indicating strong demand and clinical value [3][9] - The company decided to discontinue the IDgenetix test offering effective May 2025 [4][12] Cash Position - As of March 31, 2025, the company's cash, cash equivalents, and marketable investment securities totaled $275.2 million [5] Future Outlook - The company anticipates total revenue in 2025 to be between $287-297 million, reflecting confidence in continued growth [6] - Castle Biosciences is focused on expanding its proprietary test portfolio and enhancing patient outcomes [4][22]

Core Insights - Castle Biosciences has signed a definitive agreement to acquire Capsulomics, Inc., also known as Previse, which focuses on gastrointestinal health, particularly chronic acid reflux diseases and esophageal cancer [2][3] - The acquisition aims to enhance Castle's existing gastroenterology franchise by integrating Previse's methylation technology and other developmental technologies, thereby expanding its testing options [3][4] - The transaction is expected to close in the coming weeks, pending customary closing conditions [3] Company Overview - Castle Biosciences is a diagnostics company listed on Nasdaq (CSTL) that develops innovative tests to guide patient care and improve health outcomes [5] - The company's current portfolio includes tests for skin cancers, Barrett's esophagus, mental health conditions, and uveal melanoma, with ongoing research in other high clinical need areas [6] Previse Overview - Previse, established in 2018, specializes in gastrointestinal health and aims to improve patient outcomes through early detection and prevention of diseases like esophageal cancer [4] - The company utilizes advanced biomarker technology developed at Johns Hopkins University, which is exclusively licensed to Previse, to support its mission [4]

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its TissueCypher Barrett’s Esophagus test via two posters at the Digestive Di ...